Eptinezumab for the Prevention of Episodic Migraine Through 1 Year: Results from the Phase 3 PROMISE-1 (Prevention of Migraine via Intravenous Eptinezumab Safety and Efficacy-1) Trial

被引：0

作者：

Saper, Joel ^{[1
]}

Wilks, Kerri ^{[2
]}

Chakhava, George ^{[3
]}

Cady, Roger ^{[4
]}

Schaeffler, Barbara ^{[4
]}

Biondi, David ^{[4
]}

Hirman, Joe ^{[5
]}

Smith, Jeff ^{[6
]}

机构：

[1] Michigan Headache & Neurol Inst, Ann Arbor, MI USA

[2] Wilks & Safirstein, Hallandale Beach, FL USA

[3] Multiprofile Clin Consilium Medulla, Tbilisi, Georgia

[4] Alder BioPharmaceut Inc, Bothell, WA USA

[5] Pacific Northwest Stat Consulting Inc, Woodinville, WA USA

[6] Alder BioPharmaceut Ltd, Dublin, Ireland

来源：

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

S38.003

引用

页数：3